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Abstract 
Objectives 
This study aimed to define the problems of the current use of the e-Catalogue and the national 
formulary (NF)—two elements of medicine pricing and reimbursement policies in Indonesia for 
achieving universal health coverage (UHC)—by examining the knowledge and attitudes of 
stakeholders. Specifically, to investigate (1) the perceived challenges involved in the further 
implementation of the e-Catalogue and the NF, (2) reasons of prescribing medicines not listed in the 
NF, and (3) possible improvements in the acceptance and use of the e-Catalogue and the NF. 
Methods 
Semi-structured interviews were conducted with stakeholders (policymakers, healthcare providers, a 
pharmaceutical industry representative, and experienced patients) to collect the qualitative data. The 
data was analysed using directed content analysis, following the guidelines of the COnsolidated criteria 
for REporting Qualitative studies (COREQ) in reporting the findings. 
Results 
Interestingly, 20 of 45 participants decided to withdraw from the interview due to their lack of 
knowledge of the e-Catalogue and the NF. All 25 stakeholders who fully participated in this research 
were in favor of the e-Catalogue and the NF. However, interviewees identified a range of challenges. 
A major challenge was the lack of harmonization between the lists of medicines in the e-Catalogue 
and the NF. Several system and personal reasons for prescribing medicines not listed in the NF were 
identified. Important reasons were a lack of incentives for physicians as well as a lack of transparent 
and evidence-based methods of selection for the medicines to be listed in the NF. 
Conclusions 
The e-Catalogue and the NF have not been fully utilized for achieving UHC in Indonesia. Some 
possible improvements suggested were harmonization of medicines listed in the e-Catalogue and the 
NF, restructuring incentive programs for prescribing NF medicines, and increasing the transparency 
and evidence-based approach for selection of medicines listed in the e-Catalogue and the NF. 
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